In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biogen, NsGene co-develop neurotrophic protein

Executive Summary

Biogen and NsGene (recent spin-off from NeuroSearch; developing CNS gene and cell therapy products) will co-develop neublastin, a neurotrophic factor discovered by NsGene. Biogen gets rights to the protein and its derivatives for treating multiple sclerosis and all areas outside of the central nervous system.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies